The successes and failures of HIV drug discovery

Bibliography

• Barre-Sinoussi F, Chermann JC, Rey F, Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-71
   PubMed Web of Science ®Google Scholar
• Mitsuya H, Erickson J. Drug development. A. Discovery and development of antiretroviral therapeutics for HIV infection. In: Merigan TC, Bartlett JG, Bolognesi D. editors. Textbook of AIDS Medicine. Williams & Wilkins; Baltimore; 1999. p. 751-80
   Google Scholar
• Alkhatib G, Combadiere C, Broder CC, CC CKRS: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-8
   PubMed Web of Science ®Google Scholar
• Choe H, Farzan M, Sun Y, The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;6:1135-48
   Google Scholar
• Deng HK, Liu R, Ellmeier W, Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-6
   PubMed Web of Science ®Google Scholar
• Doranz BJ, Rucker J, Yi YJ, A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85:1149-58
   PubMed Web of Science ®Google Scholar
• Dragic T, Litwin V, Allaway GP, HIV-1 entry into CD4(+) cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-73
   PubMed Web of Science ®Google Scholar
• Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-7
   PubMed Web of Science ®Google Scholar
• Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998;93:681-4
   PubMed Web of Science ®Google Scholar
• Wild CT, Greenwell TK, Matthews TJ, A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993;9:1051-3
   PubMed Web of Science ®Google Scholar
• Walker DK, Abel S, Comby P, Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 2005;33:587-95
   PubMed Web of Science ®Google Scholar
• Cahn P, Sued O. Raltegravir: a new antiretroviral class for salvage therapy. Lancet 2007;369:1235-6
   PubMed Web of Science ®Google Scholar
• Grinsztejn B, Nguyen B-Y, Katlama C, Safety and efficacy of the HIV-1 integrase inhibitor Raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007;369:1261-9
   PubMed Web of Science ®Google Scholar
• Lu M, Blacklow SC, Kim PS. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995;2:1075-82
   PubMedGoogle Scholar
• Shimura K, Nameki D, Kajiwara K, Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors. J Biol Chem 2010;285:39471-80
   PubMed Web of Science ®Google Scholar
• Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-73
   PubMed Web of Science ®Google Scholar
• Otaka A, Nakamura M, Nameki D, Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew Chem Int Ed 2022;41:2937-40
   Google Scholar
• Nishikawa H, Nakamura S, Kodama E, Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to Enfuvirtide. Int J Biochem Cell Biol 2009;41:891-9
   PubMed Web of Science ®Google Scholar
• Liu S, Lu H, Xu Y, Different from the HIV fusion inhibitor C34, the anti-HIV drug fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 2005;280:11259-73
   PubMed Web of Science ®Google Scholar
• Derdeyn CA, Decker JM, Sfakianos JN, Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 2001;75:8605-14
   PubMed Web of Science ®Google Scholar
• Veiga AS, Santos NC, Loura LM, HIV fusion inhibitor peptide T-1249 is able to insert or adsorb to lipidic bilayers. Putative correlation with improved efficiency. J Am Chem Soc 2004;126:14758-63
   PubMed Web of Science ®Google Scholar
• Pierson TC, Doms RW, Pohlmann S. Prospects of HIV-1 entry inhibitors as novel therapeutics. Rev Med Virol 2004;14:255-70
   PubMed Web of Science ®Google Scholar
• Liu S, Jiang S. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques. Curr Pharm Des 2004;10:1827-43
   PubMed Web of Science ®Google Scholar
• Si Z, Madani N, Cox JM, Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci USA 2004;101:5036-41
   PubMed Web of Science ®Google Scholar
• Ferrer M, Kapoor TM, Strassmaier T, Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat Struct Biol 1999;6:953-60
   PubMedGoogle Scholar
• Nakahara T, Nomura W, Ohba K, Remodeling of dynamic structures of HIV-1 envelope proteins leads to synthetic antigen molecules inducing neutralizing antibodies. Bioconjug Chem 2010;21:709-14
   PubMed Web of Science ®Google Scholar
• Zwick MB, Saphire EO, Burton DR. gp41: HIV's shy protein. Nat Med 2004;10:133-4
   PubMed Web of Science ®Google Scholar
• Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;14:657-700
   Google Scholar
• Abel S, Russell D, Whitlock LA, Assessment of the absorption, metabolism and absolute bioavailability of Maraviroc in healthy male subjects. Br J Clin Pharmacol 2008;65:60-7
   PubMed Web of Science ®Google Scholar
• Chan PLS, Weatherley B, McFadyen L, A population pharmacokinetic meta-analysis of Maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. Br J Clin Pharmacol 2008;65:76-85
   PubMed Web of Science ®Google Scholar
• Stupple PA, Batchelor DV, Corless M, An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: The discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798). J Med Chem 2011;54:67-77
   PubMed Web of Science ®Google Scholar
• Baba M, Nishimura O, Kanzaki N, A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999;96:5698-703
   PubMed Web of Science ®Google Scholar
• Shiraishi M, Aramaki Y, Seto M, Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: Synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J Med Chem 2000;43:2049-63
   PubMed Web of Science ®Google Scholar
• Imamura S, Ishihara Y, Hattori T, CCR5 antagonists as anti-HIV-1 agents. 1. Synthesis and biological evaluation of 5-oxopyrrolidine-3-carboxamide derivatives. Chem Pharm Bull 2004;52:63-73
   PubMed Web of Science ®Google Scholar
• Imamura S, Ichikawa T, Nishikawa Y, Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent anti-HIV-1 activity. J Med Chem 2006;49:2784-93
   PubMed Web of Science ®Google Scholar
• Tagat JR, McCombie SW, Nazareno DV, Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)-phenyl}ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonists. J Med Chem 2003;47:2405-8
   Web of Science ®Google Scholar
• Landovitz RJ, Angel JB, Hoffmann C, Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis 2008;198:1113-22
   PubMed Web of Science ®Google Scholar
• Gathe J, Diaz R, Fatkenheuer G, Phase 3 trials of Vicriviroc in treatment-experienced subjects demonstrate safety but not significantly superior efficacy over potent background regimens. 17th CROI Conference on Retroviruses and Opportunistic Infections; 16 – 19 February 2010; San Francisco CA
   Google Scholar
• Habashita H, Kokubo M, Hamano S, Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists. J Med Chem 2006;49:4140-52
   PubMed Web of Science ®Google Scholar
• Muller A, Homey B, Soto H, Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6
   PubMed Web of Science ®Google Scholar
• Tamamura H, Hori A, Kanzaki N, T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett 2003;550:79-83
   PubMed Web of Science ®Google Scholar
• Takenaga M, Tamamura H, Hiramatsu K, A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem Biophys Res Commun 2004;320:226-32
   PubMed Web of Science ®Google Scholar
• Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. Distinctive features of “nurselike” cells that differentiate in the context of chronic lymphocytic leukemia. Blood 2002;99:1030-7
   PubMed Web of Science ®Google Scholar
• Juarez J, Bradstock KF, Gottlieb DJ, Bendall LJ. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 2003;17:1294-300
   PubMed Web of Science ®Google Scholar
• Nanki T, Hayashida K, EI-Gabalawy HS, Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4(+) T cell accumulation in rheumatoid arthritis synovium. J Immunol 2000;165:6590-8
   PubMed Web of Science ®Google Scholar
• Tamamura H, Fujisawa M, Hiramatsu K, Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent. FEBS Lett 2004;569:99-104
   PubMed Web of Science ®Google Scholar
• Tamamura H, Xu Y, Hattori T, A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun 1998;253:877-82
   PubMed Web of Science ®Google Scholar
• Tamamura H, Hiramatsu K, Kusano S, Synthesis of potent CXCR4 inhibitors possessing low cytotoxicity and improved biostability based on T140 derivatives. Org Biomol Chem 2003;1:3656-62
   PubMed Web of Science ®Google Scholar
• Tamamura H, Hiramatsu K, Mizumoto M, Enhancement of the T140-based pharmacophores leads to the development of more potent and bio-stable CXCR4 antagonists. Org Biomol Chem 2003;1:3663-9
   PubMed Web of Science ®Google Scholar
• Fujii N, Oishi S, Hiramatsu K, Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries. Angew Chem Int Ed 2003;42:3251-3
   PubMed Web of Science ®Google Scholar
• Schols D, Struyf S, Van Damme J, Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997;186:1383-8
   PubMed Web of Science ®Google Scholar
• De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003;2:581-7
   PubMed Web of Science ®Google Scholar
• Pettersson S, Perez-Nueno VI, Mena MP, Novel monocyclam derivatives as HIV entry inhibitors: design, synthesis, anti-HIV evaluation, and their interaction with the CXCR4 co-receptor. ChemMedChem 2010;5:1272-81
   PubMed Web of Science ®Google Scholar
• Weiqiang Z, Zhongxing L, Aizhi Z, Discover of small molecule CXCR4 Antagonists. J Med Chem 2007;50:5655-64
   PubMed Web of Science ®Google Scholar
• Zhu A, Zhan W, Liang Z, Dipyridine amines: a novel class of chemokine receptor type 4 antagonists with high specificity. J Med Chem 2010;53:8556-68
   PubMed Web of Science ®Google Scholar
• Bridger GJ, Skerlj RT, Hernandez-Abad PE, Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication. J Med Chem 2010;53:1250-60
   PubMed Web of Science ®Google Scholar
• Skerlj RT, Bridger GJ, Kaller A, Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem 2010;53:3376-88
   PubMed Web of Science ®Google Scholar
• De Clercq E. New anti-HIV agents and targets. Med Res Rev 2002;22:531-65
   PubMed Web of Science ®Google Scholar
• Stone ND, Dunaway SB, Flexner C, Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother 2007;51:2351-8
   PubMed Web of Science ®Google Scholar
• Gudmundsson KS, Sebahar PR, Richardson LD, Amine substituted N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-tetrahydro-8-quinolinamines as CXCR4 antagonists with potent activity against HIV-1. Bioorg Med Chem Lett 2009;19:5048-52
   PubMed Web of Science ®Google Scholar
• Miller JF, Turner EM, Gudmundsson KS, Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents. Bioorg Med Chem Lett 2010;20:2125-8
   PubMed Web of Science ®Google Scholar
• Catalano JG, Gudmundsson KS, Svolto A, Synthesis of a novel tricyclic 1,2,3,4,4a,5,6,10b-octahydro-1,10-phenanthroline ring system and CXCR4 antagonists with potent activity against HIV-1. Bioorg Med Chem Lett 2010;20:2186-90
   PubMed Web of Science ®Google Scholar
• Ueda S, Kato M, Inuki S, Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach. Bioorg Med Chem Lett 2008;18:4124-9
   PubMed Web of Science ®Google Scholar
• Tamamura H, Ojida A, Ogawa T, Identification of a new class of low molecular weight antagonists against the chemokine receptor CXCR4 having the dipicolylamine-zinc(II) complex structure. J Med Chem 2006;49:3412-15
   PubMed Web of Science ®Google Scholar
• Tanaka T, Narumi T, Ozaki T, Azamacrocyclic metal complexes as CXCR4 antagonists. ChemMedChem 2011;6:834-9
   PubMed Web of Science ®Google Scholar
• Ichiyama K, Yokoyama-Kumakura S, Tanaka Y, A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 2003;100:4185-90
   PubMed Web of Science ®Google Scholar
• Iwasaki Y, Akari H, Murakami T, Efficient inhibition of SDF-1alpha-mediated chemotaxis and HIV-1 infection by novel CXCR4 antagonists. Cancer Sci 2009;100:778-81
   PubMed Web of Science ®Google Scholar
• Percherancier Y, Berchiche YA, Slight I, Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo- and heterodimers. J Biol Chem 2005;280:9895-903
   PubMedGoogle Scholar
• Berchiche YA, Chow KY, Lagane B, Direct assessment of CXCR4 mutant conformations reveals complex link between receptor structure and G(alpha)(i) activation. J Biol Chem 2007;282:5111-15
   PubMed Web of Science ®Google Scholar
• Tanaka T, Nomura W, Narumi T, Bivalent ligands of CXCR4 with rigid linkers for elucidation of the dimerization state in cells. J Am Chem Soc 2010;132:15899-901
   PubMed Web of Science ®Google Scholar
• Asante-Appiah E, Skalka AM. Molecular mechanisms in retrovirus DNA integration. Antiviral Res 1997;36:139-56
   PubMed Web of Science ®Google Scholar
• Hindmarsh P, Leis J. Retroviral DNA integration. Microbiol Mol Biol Rev 1999;63:836-43
   PubMed Web of Science ®Google Scholar
• Ellison V, Brown PO. A stable complex between integrase and viral DNA ends mediates human immunodeficiency virus integration in vitro. Proc Natl Acad Sci USA 1994;91:7316-20
   PubMed Web of Science ®Google Scholar
• Vink C, Lutzke RAP, Plasterk RHA. Formation of a stable complex between the human immunodeficiency virus integrase protein and viral DNA. Nucleic Acids Res 1994;22:4103-10
   PubMed Web of Science ®Google Scholar
• Wolfe AL, Felock PJ, Hastings JC, The role of manganese in promoting multimerization and assembly of human immunodeficiency virus type 1 integrase as a catalytically active complex on immobilized long terminal repeat substrates. J Virol 1996;70:1424-32
   PubMed Web of Science ®Google Scholar
• Grobler JA, Stillmock K, Hu B, Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci USA 2002;99:6661-6
   PubMed Web of Science ®Google Scholar
• Hazuda DJ, Young SD, Guare JP, Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004;305:528-32
   PubMed Web of Science ®Google Scholar
• Little S, Drusano G, Schooley R, Abstract 161, 12th Conference of Retroviruses and Opportunistic Infections; Boston, MA; 2005
   Google Scholar
• Reddy YS, Min SS, Borland J, Safety and pharmacokinetics of GSK364735, a human immunodeficiency virus type 1 integrase inhibitor, following single and repeated administration in healthy adult subjects. Antimicrob Agents Chemother 2007;51:4284-9
   PubMed Web of Science ®Google Scholar
• Jones GS, Yu F, Zeynalzadegan A, Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 2009;53:1194-203
   PubMed Web of Science ®Google Scholar
• Ferrara M, Crescenzi B, Donghi M, Synthesis of a hexahydropyrimido[1,2-a]azepine-2-carboxamide derivative useful as an HIV integrase inhibitor. Tetrahedron Lett 2007;48:8379-82
   Web of Science ®Google Scholar
• Sato M, Motomura T, Aramaki H, Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem 2006;49:1506-8
   PubMed Web of Science ®Google Scholar
• DeJesus E, Berger D, Markowitz M, Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006;43:1-5
   PubMed Web of Science ®Google Scholar
• Mathias AA, German P, Murray BP, Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010;87:322-9
   PubMed Web of Science ®Google Scholar
• Marinello J, Marchand C, Mott BT, Comparison of Raltegravir and Elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 2008;47:9345-54
   PubMed Web of Science ®Google Scholar
• Bar-Magen T, Sloan RD, Donahue DA, Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol 2010;84:9210-16
   PubMed Web of Science ®Google Scholar
• Johns BA, Svolto AC. Advances in two-metal chelation inhibitors of HIV integrase. Expert Opin Ther Patents 2008;18:1225-37
   Web of Science ®Google Scholar
• Min S, Song I, Borland J, Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2010;54:254-8
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Yoshinaga T, Seki T, In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011;55:813-21
   PubMed Web of Science ®Google Scholar
• Ovenden SP, Yu J, Wan SS, Globoidnan A: a lignan from Eucalyptus globoidea inhibits HIV integrase. Phytochemistry 2004;65:3255-9
   PubMed Web of Science ®Google Scholar
• Valkov E, Gupta SS, Hare S, Functional and structural characterization of the integrase from the prototype foamy virus. Nucleic Acids Res 2009;37:243-55
   PubMed Web of Science ®Google Scholar
• Hare S, Gupta SS, Valkov E, Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010;464:232-6
   PubMed Web of Science ®Google Scholar
• De Luca L, De Grazia S, Ferro S, HIV-1 integrase strand-transfer inhibitors: design, synthesis and molecular modeling investigation. Eur J Med Chem 2011;46:756-64
   PubMed Web of Science ®Google Scholar
• Suzuki S, Urano E, Hashimoto C, Peptide HIV-1 integrase inhibitors from HIV-1 gene products. J Med Chem 2010;53:5356-60
   PubMed Web of Science ®Google Scholar
• Suzuki S, Maddali K, Hashimoto C, Peptidic HIV integrase inhibitors derived from HIV gene products: structure–activity relationship studies. Bioorg Med Chem 2010;18:6771-5
   PubMed Web of Science ®Google Scholar
• Zhao Q, Ma L, Jiang S, Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 2005;339:213-25
   PubMed Web of Science ®Google Scholar
• Schon A, Madani N, Klein JC, Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry 2006;45:10973-80
   PubMed Web of Science ®Google Scholar
• Yamada Y, Ochiai C, Yoshimura K, CD4 mimics targeting the mechanism of HIV entry. Bioorg Med Chem Lett 2010;20:354-8
   PubMed Web of Science ®Google Scholar
• Narumi T, Ochiai C, Yoshimura K, CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist. Bioorg Med Chem Lett 2010;20:5853-8
   PubMed Web of Science ®Google Scholar
• Yoshimura K, Harada S, Shibata J, Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J Virol 2010;84:7558-68
   PubMed Web of Science ®Google Scholar
• Lalonde JM, Elban MA, Courter JR, Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening. Bioorg Med Chem 2011;19:91-101
   PubMed Web of Science ®Google Scholar
• Lu RJ, Tucker JA, Zinevitch T, Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group. J Med Chem 2007;50:6535-44
   PubMed Web of Science ®Google Scholar
• Zou Y-R, Kottmann AH, Kuroda M, Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998;393:595-9
   PubMed Web of Science ®Google Scholar
• Nakata H, Steinberg SM, Koh Y, Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs. Antimicrob Agents Chemother 2008;52:2111-19
   PubMed Web of Science ®Google Scholar
• Abraham M, Biyder K, Begin M, Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells 2007;25:2158-66
   PubMed Web of Science ®Google Scholar
• Broxmeyer HE, Orschell CM, Clapp DW, Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005;201:1307-18
   PubMed Web of Science ®Google Scholar
• Liles WC, Broxmeyer HE, Rodger E, Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003;102:2728-30
   PubMed Web of Science ®Google Scholar
• Koh Y, Nakata H, Maeda K, Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003;47:3123-9
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Sridhar PR, Leshchenko S, Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. J Med Chem 2006;49:5252-61
   PubMed Web of Science ®Google Scholar
• Thayer AM. This is the news from Chemical & Engineering News, American Chemical Society. p29, 2008
   Google Scholar